February 7, 2014
Turning the Tide: Staging
Improvements in liver monitoring continue to lag behind. Cox pointed out that a number of less-invasive blood tests -- FibroTest, SHASTA, FIB-4, Forns and APRI, for instance -- have been shown to have some value. "In this very inexpensive test, the AST to platelet ratio index is actually pretty good at predicting liver disease when compared to liver biopsy -- which again, isn't perfect," Cox said.
A newer, more advanced, completely non-invasive method -- transient elastography (a.k.a. FibroScan), approved in the U.S. in 2013 -- appears quite useful for picking up high-level liver disease and relatively useful for spotting lower-level disease, Cox said. However, the test -- which gauges liver stiffness by passing ultrasound waves through the organ -- is less effective the more overweight a patient is, and with an average price tag in the $120,000 range, Cox suggested that the technology remained an option that many facilities were unable to afford.
Myles Helfand is the editorial director of TheBody.com and TheBodyPRO.com.
Follow Myles on Twitter: @MylesatTheBody.
|HIV and Cardiovascular Disease|
|This Week in HIV Research: Helping HIV-Positive Smokers Quit; Alcohol and Sexual Decision-Making; Gender Differences; and More|
|Higher CD4 Counts -- But Not Statins -- Cut Risk of Heart Attack, Stroke and Mortality|
|ChemSex Versus Recreational Drug Use: A Proposed Definition for Health Workers|
|Diabetes Risk, Screening and Monitoring in People With HIV|
|High-Dose Vitamin D Supplementation Lowers HIV Replication In Vitro|